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Abstract 
Genetic variation in AKT1 may be associated with sensitivity to the psychotomimetic effects 
of cannabis as well as with increased risk for psychotic disorder following cannabis use. 
Investigation of the effect of this interaction on relevant intermediate phenotypes for 
psychosis, such as cognition, may help to clarify the underlying mechanism. Thus, verbal 
memory (visually-presented Word Learning Task, WLT), sustained attention (Continuous 
Performance Test, CPT), AKT1 rs2494732 genotype and cannabis use were examined in a 
large cohort of patients with psychotic disorder. No evidence was found for AKT1 X cannabis 
interaction on verbal memory. Cannabis use preceding onset of psychotic disorder did 
interact significantly with AKT1 rs2494732 genotype to affect CPT reaction time (β= 8.0, SE 
3.9, p =.037) and CPT accuracy (β= -1.2, SE 0.4, p =.003). Cannabis-using patients with the a 
priori vulnerability C/C genotype were slower and less accurate on the CPT, whereas 
cannabis-using patients with the T/T genotype had similar or better performance than non-
using patients with psychotic disorder. The interaction was also apparent in patients with 
psychotic disorder who had not used cannabis in the 12 months preceding assessment, but 
was absent in the unaffected siblings of these patients and in healthy controls. In conclusion, 
cannabis use prior to onset of psychosis may have long-lasting effects on measures of 
sustained attention, even in the absence of current use, contingent on AKT1 rs2494732 
genotype. The results suggest that long-term changes in cognition may mediate the risk-
increasing effect of the AKT1 X cannabis interaction on psychotic disorder.  
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Introduction  
There is growing evidence from epidemiological studies that cannabis use acts as a 
component cause for psychotic disorder resulting in an approximate two-fold increase in risk 
(Henquet et al, 2005; Moore et al, 2007). An important consideration regarding the possible 
causality of the cannabis-psychosis relationship is that only a minority of users develops a 
psychotic disorder, suggesting that underlying vulnerability is of crucial importance. A recent 
study by the Dutch Genetic Risk and Outcome in Psychosis (GROUP) consortium examined a 
national sample of 1100 sib-pairs discordant for psychotic disorder and found evidence that 
genetic risk for schizophrenia is expressed, at least partly, as vulnerability for the 
psychotomimetic effect of cannabis (Genetic Risk and Outcome of Psychosis (GROUP) 
Investigators, 2011).  
In addition to transient psychotic experiences and negative symptoms, cannabis disrupts 
cognitive performance when acutely administered (D'Souza et al, 2004; Solowij and Michie, 
2007). Compared with healthy controls, patients with schizophrenia were also found to be 
more vulnerable to the deleterious effects of cannabis on cognition, specifically memory and 
learning (D'Souza et al, 2005), again suggesting that vulnerability to schizophrenia may be 
expressed as an increased sensitivity to the effect of cannabis (D'Souza et al, 2005).  
Whether chronic cannabis use may have persistent effects on cognitive performance is still a 
matter of debate. Some studies have suggested that chronic cannabis use may produce 
long-lasting cognitive deficits (Bolla et al, 2002; Pope and Yurgelun-Todd, 1996), whereas 
other have reported effects on cognition that were reversed after ∆9-THC -withdrawal (Fried 
et al, 2005; Pope et al, 2002). Since cognitive underachievement is one of the most 
replicated findings in patients with schizophrenia (Heinrichs and Zakzanis, 1998) and several 
studies have also suggested that deterioration of cognition may precede the first episode of 
psychosis (Seidman et al, 2010; Van Oel et al, 2002; van Winkel et al, 2007; van Winkel et al, 
2006), cannabis-induced cognitive changes may have considerable relevance for the risk-
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increasing effect of cannabis on psychotic disorder (D'Souza et al, 2005). Consistent with this 
hypothesis, cannabis use was found to be associated with reduced hippocampal and 
amygdala volume in healthy controls (Yücel et al, 2008) and with excessive cortical thinning 
in patients with a psychotic disorder compared to cannabis-using healthy controls (Habets et 
al, 2011). In addition, cannabis-using patients with schizophrenia were found to have larger 
reductions of gray matter volume than non-using schizophrenia patients (Rais et al, 2008), 
especially in areas with high expression of cannabinoid type 1 (CB1) receptors (Rais et al, 
2010). The relationship between cannabis and cognition in patients with schizophrenia may 
be more complex, however, as recent meta-analyses found that in patients with 
schizophrenia, lifetime cannabis use is associated with better rather than worse cognitive 
performance (Rabin et al, 2011; Yücel et al, 2010).  
Our group recently reported that a single nucleotide polymorphism (SNP) in AKT1 
(rs2494732) moderated the short-term psychotomimetic effects of recent cannabis use, 
determined by urinalysis, in the healthy siblings of patients with a psychotic disorder (van 
Winkel and Genetic Risk and Outcome of Psychosis (GROUP) Investigators, 2011). In 
addition, across different samples and epidemiological approaches of gene-environment 
interaction, this SNP also consistently moderated risk for psychotic disorder following 
cannabis use. Carriers of the AKT1 rs2494732 C/C genotype had an approximately two-fold 
odds of being diagnosed with a psychotic disorder, but only in the context of cannabis use 
(van Winkel et al, 2011).   
AKT1 is a protein kinase that is involved in multiple cellular functions including metabolism, 
cell stress, cell-cycle regulation, and apoptosis (Freyberg et al, 2010). It has a basic role in 
regulating neuronal cell size and survival (Franke, 2008) and is also a key signaling molecule 
downstream of the dopamine D2 (DRD2) receptor; decreased AKT1 functionality may result 
in exacerbated responses to DRD2 receptor stimulation (Arguello and Gogos, 2008). 
Decreased AKT1 levels have been observed in lymphoblasts and postmortem prefrontal 
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cortex of patients with schizophrenia (Emamian et al, 2004; Thiselton et al, 2008), and 
several studies have shown evidence for genetic association with schizophrenia (Bajestan et 
al, 2006; Ikeda et al, 2004; Norton et al, 2007; Schwab et al, 2005; Thiselton et al, 2008), 
although not all studies were able to confirm this (Ide et al, 2006; Liu et al, 2009).  
Cannabinoids are able to activate the AKT1/GSK3 pathway by acting on CB1 and CB2 
receptors in vitro (Sanchez et al, 2003) and acute administration of THC in mice also 
activated AKT1 in vivo (through AKT1 phosphorylation) in several brain areas, including the 
striatum, independent of dopamine D1 and D2 receptor blockade (Ozaita et al, 2007). 
Interestingly, a haplotype consisting of the AKT rs3730358, rs1130233 and rs2494732 G-A-C 
alleles was associated with worse performance on the N-back task in a group of healthy 
volunteers (Tan et al, 2008). Optimal execution of this task critically depends on proper 
levels of dopamine within the prefrontal cortex (Winterer and Weinberger, 2004). 
Given the above, genetic variation in AKT1 may play a role into the degree to which cannabis 
use induces cognitive alterations in the trajectory towards psychotic disorder. Detectable 
genetic moderation of cognitive alterations in cannabis-using individuals with psychotic 
disorder would provide a biological substrate for the hypothesized etiological relevance of 
the AKT1 rs2494732 X cannabis interaction. This hypothesis would be further strengthened 
if this particular interaction would also be detectable in patients with past but not current 
cannabis use, as this would circumvent confounding by the effects of current use. The 
present study examined these hypotheses in a large sample of patients with psychotic 
disorder.  
 
Methods 
Measures 
Cannabis and other drug measures 
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Cannabis and other drug measures were derived from the Composite International 
Diagnostic Interview (CIDI) and used consistently with previous papers (Genetic Risk and 
Outcome of Psychosis (GROUP) Investigators, 2011; van Winkel et al, 2011). The main 
cannabis measure for the current analysis was CIDI cannabis pattern of use during the 
lifetime period of heaviest use, restricted to those individuals whose age in the period of 
most heavy use preceded onset of psychosis ([hereafter: CIDI lifetime use]: none [0], less 
than weekly [1] weekly [2] and daily [3]). Onset of psychosis was defined as the first mental 
health contact for psychosis. Given the relatively low rates of CIDI lifetime cannabis use with 
a frequency of less than weekly and weekly compared to daily use (see (van Winkel et al, 
2011)), the ‘less than weekly’ and ‘weekly’ categories were joined for the stratified analyses. 
CIDI lifetime use was the main cannabis measure since long-term changes in cognition were 
the subject of the present analyses. A second measure was frequency of cannabis use in the 
12 months preceding assessment as reported in the CIDI (none [0], less than weekly [1] 
weekly [2] and daily [3]). A third measure was recent cannabis use, as established by 
urinalysis (negative [0], positive [1]), which was used to control, by exclusion, for the 
cognitive effects of recent cannabis use. Urinalysis was carried out as a screen for the 
presence of cannabis at the national Alcohol- and Drug use Jellinek Laboratory. The method 
used was immunoassays with a cut off of 50ng/ml. In addition, as an integrity parameter, 
the creatinine level of every sample was measured. Cannabis urine screening has a detection 
window up to 30 days, but the detection time has been documented in literature to be even 
longer (up to three months), depending on level of cannabis use (Musshoff and Madea, 
2006). Given the relatively high cut-off level of 50ng/ml, a conservative detection window of 
one month can be inferred. Thus, a positive urinalysis result could indicate acute intoxication 
at the time of the testing. Amphetamine and cocaine use measures were similar to the 
cannabis use measures: CIDI lifetime use (none [0], less than weekly [1] weekly [2] and daily 
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[3]) and urinalysis (negative [0], positive [1]). Significant use of alcohol was defined as 
drinking more than 12 units per week in the last 12 months (negative [0], positive [1]). 
 
Cognitive assessments 
Since a previous study in patients with psychosis and healthy controls found genetic 
moderation of cannabis-induced cognitive impairments of verbal memory and especially 
sustained attention (Henquet et al, 2006), these were selected as the cognitive outcome 
measures. The standardized Dutch version of the visually-presented Word Learning Task 
(WLT) was used to assess memory storage and retrieval of 15 monosyllabic nonrelated 
words from episodic memory (immediate recall, delayed recall and recognition after 20 
minutes (Van Der Elst et al, 2005). Due to technical problems, less than 50% of the sample 
had reliable data on the WLT-recognition (Meijer et al, submitted), therefore these data 
were not analyzed. Sustained attention was evaluated with the Continuous Performance 
Test (CPT) with working memory load, known in the literature as CPT-AX (Nuechterlein and 
Dawson, 1984). Responses were expressed as the percentage of correct detections 
(‘accuracy’), reaction time of correct detections and false alarms (Nuechterlein et al, 1984). 
IQ was measured using the abbreviated version of the Wechsler Adult Intelligence Scale, 
version III (Blyler et al, 2000). Research assistants responsible for the neuropsychological 
testing received a comprehensive training, in order to standardize the assessments. The 
assessment was conducted in standardized conditions: in a fixed order on standardized 
computers in a quiet environment. 
 
AKT1 genotype 
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AKT1 rs2494732 genotype was determined by Sequenom (Hamburg, Germany) using the 
Sequenom MassARRAY iPLEX platform at the facilities of the manufacturer, as described in 
previous work (van Winkel et al, 2011). 
 
Sample  
In selected representative geographical areas in the Netherlands and Belgium, patients were 
identified through representative clinicians working in regional psychotic disorder services, 
whose caseload was screened for inclusion criteria. Subsequently, a group of patients 
presenting consecutively at these services either as outpatients or in-patients were recruited 
for the study. Controls were selected through a system of random mailings to addresses in 
the catchment areas of the cases.  
The full GROUP sample consists of 1120 patients with non-affective psychotic disorder, 1057 
siblings of these 1120 patients, 919 parents of the patients and their siblings and 590 
unrelated controls. Inclusion criteria were: (i) age range 16 to 50 years, (ii) diagnosis of non-
affective psychotic disorder and (iii) good command of Dutch language. Controls had no 
first- or second-degree relative with a psychotic disorder as established by the Family 
Interview for Genetic Studies (NIMH.Genetics.Initiative, 1992) with the control as the 
informant. Diagnosis was based on the Diagnostic and Statistical Manual of Mental Disorder-
IV (DSM-IV) criteria (American Psychiatric Association, 2000), assessed with the 
Comprehensive Assessment of Symptoms and History (CASH) interview (Andreasen et al, 
1992) or Schedules for Clinical Assessment for Neuropsychiatry (SCAN 2.1)(Wing et al, 1990). 
Of 1120 patients included, genetic data were available in 801 (76.8% male, mean age 27.9 
[SD 8.2]). No large or significant differences in age, sex, CIDI lifetime use or recent use of 
cannabis, cocaine or amphetamines were found for patients who did or did not provide DNA 
((van Winkel et al, 2011)). The WLT was administered in 763 and the CPT in 714 of the 
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patients for whom genetic data were available. Of the 714 patients for whom both genetic 
and all cognitive data were available, there were 438 lifetime cannabis users, 335 of whom 
(76.5 %) had experienced their lifetime period of most intensive use before the onset of 
psychosis. Since we intended to analyze the etiological relevance of the hypothesized effects 
of cannabis use on cognitive alterations in psychotic disorder, patients whose period of 
heaviest use occurred after onset of psychosis (n=103) were excluded, resulting in a final 
sample of 654 (WLT)/611 (CPT) patients for analysis (table 1). 790 siblings and 414 controls 
were available for the case-sib and case-control comparisons of the WLT, respectively, 
whereas 738 siblings and 379 controls were available for the sensitivity analysis as regards 
the CPT.  
DSM-IV diagnoses of the patients were: schizophrenia and related disorders (DSM-IV 295.x; 
n=489, 80 %), other psychotic disorders (DSM-IV 297/298; n=110, 18%), psychotic illness in 
the context of substance-abuse or somatic illness (n=5, 1%) or affective psychosis (n=7, 1%) 
although fulfilling criteria of clinical diagnosis of non-affective psychosis at study entry; these 
individuals were retained in the sample assuming subtle diagnostic changes between time 
point of identification for inclusion and actual assessment that could occur in any patient 
included in the cohort at any time point, and taking into account the fact that for the focus 
of underlying genetic liability the diagnostic change would not be relevant (Cardno et al, 
2002) (see (Genetic Risk and Outcome of Psychosis (GROUP) Investigators, 2011) for further 
details). 
 
Statistical analysis 
In order to examine the hypothesis of AKT1 X cannabis interaction, the relevant cognitive 
outcome was regressed on cannabis use, AKT1 rs2494732 genotype, and their interaction. 
Genotypes were coded 0, 1 or 2 and modeled as a linear effect, since this method can deal 
 10
with different genotype distributions, including distributions with a low minor allele 
frequency, as it avoids stratification into small subgroups (Cordell and Clayton, 2005). 
Cannabis use was similarly analyzed as a linear effect, as also applied in a previous paper 
(van Winkel et al, 2011). Only patients for whom the most intensive period of use preceded 
the onset of psychosis, defined as the first mental health contact for psychotic symptoms, 
were included in the analyses. Given the fact that some families contributed more than one 
patient, hierarchical clustering of data at the level of family was taken into account using the 
multilevel random regression XTREG routine in STATA, version 11 (StataCorp., 2009). 
Analyses concerning the effect of AKT1 genotype on measures of cognition were adjusted 
for the following a priori confounders: age, sex and IQ. Analyses involving cannabis (both 
main effects and interactions with AKT1 genotype) were additionally controlled for cigarette 
use, alcohol use, recent use of cannabis (by urinalysis), use of amphetamines (lifetime and 
by urinalysis) and use of cocaine (lifetime and by urinalysis).  
Since a positive urinalysis result could indicate acute intoxication at the time of the testing, a 
sensitivity analysis examined AKT1 moderation of cannabis-induced cognitive alterations in 
patients with established absence of use, in order to separate the hypothesized long-term 
effects from the effects of recent use. Thus, patients who experienced the period of most 
intensive use prior to illness onset, reported no use of cannabis in the last year and for 
whom urinalysis confirmed the absence of current cannabis use were included in this 
sensitivity analysis. A second analysis examined whether significant interactions (at p <.05) 
were associated with (development of) psychotic disorder by fitting the three-way 
interaction between AKT1 genotype, CIDI lifetime use and group status, using case-sibling 
and a case-control comparisons. These analyses were also adjusted for age, sex, IQ and 
cigarette use. 
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Results 
Cannabis use 
Cannabis use was highly prevalent in the sample of 611 patients for whom all data were 
available: only 44.5 % of the patients reported never having used cannabis. 38.0 % had used 
cannabis daily in the lifetime period of heaviest use, 10.2 % weekly and 7.4 % less than 
weekly. In addition, 15.9% tested positive for recent cannabis use (urinalysis). Cannabis 
users were significantly younger than non-users, had an earlier age at onset of psychosis, 
were more likely to be male but did not differ for intelligence quotient (table 1). Lifetime 
cocaine use was reported by 19.7% (frequency of use in the heaviest period of use: less than 
weekly 3.3%, weekly 6.1%, daily 9.3%); 0.9% tested positive for recent cocaine use by 
urinalysis. Lifetime amphetamine use was reported by 18 % (frequency of use in the heaviest 
period of use: less than weekly 4.3%, weekly 5.6%, daily 8.2%); 0.6% tested positive for 
recent amphetamine use by urinalysis. There were no large or significant differences in age, 
sex, IQ or age at onset of psychosis according to AKT1 rs2494732 genotype. 
 
Verbal memory 
In the patients with cannabis use prior to illness onset, higher frequency of CIDI lifetime use 
was not associated with immediate recall (β= -.01, SE .16, p= .97) or delayed recall (β= -.03, 
SE .09, p= .68). AKT1 rs2494732 genotype was associated with immediate recall (β= .65, SE 
.29, p= .025), but not delayed recall (β= .18, SE .14, p= .17). No evidence was found for an 
AKT1 rs2494732 X cannabis interaction on any of the verbal memory measures. 
 
Sustained attention 
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CIDI lifetime use was not associated with CPT reaction time (β= -2.4, SE 2.5, p =.34), accuracy 
(β= -0.2, SE 0.3, p =.43) or false alarms (β= 0.1, SE 0.1, p =.17). The same was true for AKT1 
rs2494732 genotype (reaction time: β= 6.9, SE 4.3, p =.12; accuracy: β= -0.6, SE 0.5, p =.26; 
false alarms: β= 0.2, SE 0.2, p =.13). CIDI lifetime use interacted significantly with AKT1 
rs2494732 genotype in its effect on CPT reaction time (β= 8.0, SE 3.9, p =.037) and accuracy 
(β= -1.2, SE 0.4, p =.003), but not false alarms (table 2). Cannabis users with the C/C 
genotype performed worst, whereas users with the T/T genotype had similar or better 
performance than the non-using groups, indicative of qualitative interaction (table 2, figure 
1). Further analysis revealed that the AKT1 X cannabis interaction was statistically significant 
only in those with a lifetime history of daily use (accuracy β= -3.76, SE 1.21, p =.002; reaction 
time β= 24.3, SE 11.8, p =.039), although the direction of the association was similar in the 
patients with weekly or less than weekly use (accuracy β= -1.5, SE 1.4, p =.29; reaction time 
β= 24.6, SE 14.3, p =.085).  
 
Sensitivity analysis in patients with established absence of use 
The sensitivity analysis revealed similar results in patients with a negative urinalysis and 
reporting absence of cannabis use in the twelve months preceding the diagnostic interview 
(table 2). Again, this was only evident in patients with a lifetime history of daily use 
(accuracy β= -4.33, SE 1.54, p =.005; reaction time β= 34.3, SE 17.5, p =.050). 
 
Sensitivity analysis regarding the specificity for psychotic disorder 
In the unaffected siblings, 62.7% reported no cannabis use; of those that did report cannabis 
use, 13.8% reported less than weekly use, 9.6% reported weekly use and 13.8% reported 
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daily use in the period of heaviest use. In the healthy controls, 69.9% reported no cannabis 
use; of those that did report cannabis use, 13.7% reported less than weekly use, 6.6% 
reported weekly use and 9.8% reported daily use in the period of heaviest use.  The reported 
AKT1 x cannabis interactions were specific to patients with psychotic disorder, at least for 
CPT- accuracy (case-sib threeway group x CIDI lifetime use x AKT1 interaction χ2 = 9.3, p = 
.002; case-control threeway group x CIDI lifetime use x AKT1 interaction χ2 = 3.2, p = .076), 
indicating that the reported AKT1 X cannabis interaction was not observed in either 
unaffected siblings (β= 0.25, SE 0.37, p =.51) or controls (β= -0.7, SE 0.46, p =.88). A similar 
trend was observed for CPT-reaction time, although this did not reach statistical significance 
(case-sib threeway interaction χ2 = 2.7, p = .10; case-control threeway interaction χ2 = 0.9, 
p = .34). 
 
Explorative analyses in patients with the heaviest period of use after illness onset 
As patients who experienced the heaviest period of use after illness onset were excluded 
from the analyses reported above, the effects of cannabis use were also explored in this 
group. In agreement with the results in the patients whose heaviest period of use preceded 
onset of psychosis, there was no association between CIDI lifetime cannabis use and 
immediate recall: (β= .07, SE .23, p= .75) or delayed recall: (β= -.13, SE .10, p= .22). The same 
was true for the CPT (reaction time: β= -5.2, SE 3.3, p =.11; accuracy: β= -0.6, SE 0.4, p =.12; 
false alarms: β= 0.6, SE 0.4, p =.13). AKT1 x cannabis interaction analyses were not fitted due 
to the lack of statistical power in this restricted sample of 103 patients. 
 
Discussion 
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The relationship between cannabis use, cognition and psychosis is complex and far from 
understood. While most studies agree that acute cannabis use is associated with cognitive 
impairments in the short-term, the long-term effects of cannabis use remain contentious. In 
schizophrenia, a recent meta-analysis reported better cognition in cannabis-using patients 
(Yücel et al, 2010).  
The current study found no clear associations between lifetime cannabis use and cognitive 
performance, i.e. verbal memory and sustained attention. However, underneath this null 
finding was significant heterogeneity. Variation in cognitive performance, particularly 
sustained attention, was associated with a polymorphism in AKT1 (rs2494732) that was also 
implicated in risk for psychotic disorder following cannabis use in the same sample (van 
Winkel et al, 2011). Cannabis users with the C/C genotype were slower and less accurate on 
the CPT, whereas users with the T/T genotype had similar or better performance than non-
using groups. The results indicate that the combined risk-increasing effects of AKT1 
rs2494732 C/C genotype and cannabis use on psychotic disorder may be accompanied by 
selective alterations in sustained attention. This is in keeping with the interpretation that in 
genetically vulnerable individuals, cannabis use may adversely impact on brain function and 
psychopathology (D'Souza et al, 2005; Genetic Risk and Outcome of Psychosis (GROUP) 
Investigators, 2011; Habets et al, 2011). The present findings are also in agreement with a 
previous study that the CPT is sensitive to genetic moderation of cognitive performance by 
cannabis in patients with schizophrenia (Henquet et al, 2006).  
Performance on the CPT critically depends on prefrontal dopamine functioning, which may 
be in agreement with a reported role of AKT1 in modulating dopamine-related prefrontal 
cortical structure and functioning (Tan et al, 2008). This is especially interesting, as COMT, 
another gene important in prefrontal dopamine availability, was also suggested to moderate 
the effects of cannabis use on expression of psychosis and cognitive performance in 
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previous studies (Caspi et al, 2005; Henquet et al, 2006; O'Tuathaigh et al, 2010). While the 
reported cognitive effects of cannabis use were subtle, the present findings are important as 
they suggest that the psychosis-inducing effects of cannabis may be driven by dopamine-
related prefrontal-striatal interactions and that genetic variation in this brain circuit may 
determine the vulnerability to these effects. 
The interpretation that the reported interaction may indicate long-term cognitive effects of 
cannabis use is supported by findings (i) that it was only present in patients with a lifetime 
history of daily use, as opposed to weekly or less often use, (ii) that it was specific to patients 
with a psychotic disorder, and (iii) that it was also apparent in patients who had not used 
cannabis in the 12 months preceding assessment, as established by the combination of a 
biological measure (urinalysis) and self-report. The combination of self-report and a 
biological measure reduces the possibility of identifying cannabis users as non-users (‘false 
negatives’), thus ensuring the reliability of the reported results. 
The current findings may seem contradictory to meta-analyses reporting superior cognitive 
performance in cannabis-using patients (Rabin et al, 2011; Yücel et al, 2010). In addition, in 
the present study, there was a suggestion that in patients with the AKT1 rs2494732 T/T 
genotype, cannabis use may be associated with a better performance on measures of 
sustained attention. Several explanations for superior cognitive abilities in cannabis-using 
patients have been put forward, including possible neuroprotective effects of cannabis in 
individuals developing psychotic symptoms (Jockers-Scherubl et al, 2007) and a selective 
mechanism of causal contribution of cannabis, such that persons with less neurocognitive 
impairment make a transition to psychotic disorder that they would not have made in the 
absence of cannabis use (Yücel et al, 2010). In our opinion, the latter explanation seems 
most plausible and is in agreement with extant literature suggesting that cannabis use is a 
component cause in the development of psychotic disorder (Murray et al, 2007). 
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Nevertheless, neuroprotective properties of exogenous cannabinoids, mediated by PI3K-
AKT1 signaling, have also been documented (Molina-Holgado et al, 2005). Thus, the 
possibility that cannabis use may have beneficial effects on cognition via AKT1-modulation in 
certain subgroups at risk for psychosis cannot be discarded.  
The results of this study need to be interpreted in the context of the risk for spurious 
association (Sullivan, 2007) or interaction (van Winkel et al, 2010) in candidate SNP studies. 
The present study analyzed a SNP in AKT1 that was identified by a systematic effort to 
unravel the genetics of cannabis-induced psychosis (van Winkel et al, 2011). In addition, the 
present study analyzed a relatively large patient sample and used cognitive tests that were 
found to be sensitive to genetic moderation of cannabis-induced deterioration of cognition 
in a previous study (Henquet et al, 2006). This should reduce the probability that the 
reported interaction is spurious; nevertheless, replication in independent samples is 
required. This study further needs to be interpreted in the context of a number of 
limitations. The most important limitation is the cross-sectional nature of the study. Since 
we have no assessment of cognition before illness onset, it is not possible to make strong 
inferences of the causal nature of the reported interaction on measures of cognition. 
Longitudinal studies are necessary to better understand interactions between the implicated 
factors. Second, differences in possible confounders related to sampling bias in users versus 
non-users (e.g. cannabis using patients were younger and more likely to be male) could 
explain part of the reported interactions. However, in order to confound interactions 
variables need to be associated with genotype, cannabis use and cognition; conditions that 
do not apply to a large number of variables. In addition, analyses were covaried for the most 
important potential confounders. The choice to selectively examine verbal memory and 
sustained attention can be interpreted as both a limitation and strength of the present work. 
The decision to analyze these domains was part of a careful strategy to reduce the possibility 
of spurious genetic association, by examining a SNP that was identified by a systematic 
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effort to unravel the genetics of cannabis-induced psychosis (van Winkel et al, 2011), using a 
large sample and using cognitive tests that were found to be sensitive to genetic moderation 
of cannabis-induced cognitive alterations (Henquet et al, 2006). Nevertheless, a larger 
cognitive battery would have allowed for a more comprehensive examination of the 
reported AKT1 x cannabis interaction. As the present work suggests that AKT1 moderation of 
cannabis-induced cognitive alterations may be specific to prefrontal-mediated cognitive 
tasks, in agreement with a role of AKT1 in regulating dopamine-related prefrontal structure 
and functioning (Tan et al, 2008), future work could examine this hypothesis more 
specifically. 
In conclusion, cannabis use prior to onset of psychotic disorder may have long-lasting effects 
on measures of sustained attention, even in the absence of current use, contingent on AKT1 
rs2494732 genotype. The results suggest that long-term changes in cognition may mediate 
the risk-increasing effect of the AKT1 X cannabis interaction on psychotic disorder. 
Prospective studies are needed to confirm these findings. 
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Tables 
Table 1. Clinical and demographic characteristics of the sample with a psychotic disorder for whom 
both genetic and cognitive data were available. 
 
Overall 
sample 
(n=611) 
No 
cannabis 
use 
(n=272) 
Cannabis 
use 
(n=339) 
P 
(never-users vs users 
of cannabis) 
Age (yr)(SD) 28.4 
(8.6) 
30.1 
(10.1) 
27.0 
(6.9) 
< .0001 
Sex (% male) 
 
75.1 60.7 86.7 < .0001 
IQ (SD) 94.6 
(16.5) 
93.9 
(17.0) 
95.1 
(16.1) 
.38 
Age at onset of psychosis (yr)(SD) 23.0 
(7.1) 
24.2 
(8.1) 
22.1 
(6.0) 
.0005 
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Table 2. Continuous Performance Test performance as a function of cannabis use and AKT1 
rs2494732 genotype. 
CANNABIS USE PRECEDING ONSET OF PSYCHOSIS (N=601*) 
 T/T C/T C/C 
P 
interaction 
 Never 
use 
(n=103) 
Use 
(n=107) 
Never 
use 
(n=125) 
Use 
(n=152) 
Never 
use 
(n=40) 
Use 
(n=74) 
 
CPT, 
accuracy 
(%)(SD) 
92.6 
(11.0) 
94.4 
(8.7) 
95.3
(8.5) 
95.4
(6.7) 
94.4 
(11.4)  
91.6
(14.9) 
.003 
CPT, 
reaction 
time 
(ms)(SD) 
434.9 
(76.9) 
412.3
(79.5) 
437.5
(87.5) 
434.1
(82.5) 
425.5
(84.7) 
439.1 
(92.2) 
.037 
CPT, false 
alarms 
(n)(SD) 
1.16 
(4.2) 
0.81 
(3.4) 
0.44
(0.8) 
1.01
(4.9) 
0.63
(1.4) 
2.05
(7.0) 
.455 
CANNABIS USE PRECEDING ONSET OF PSYCHOSIS AND ABSENCE OF RECENT USE† (N=408) 
 
T/T C/T C/C 
P 
interaction 
 Never 
use 
(n=103) 
Former 
use 
(n=51) 
Never 
use 
(n=125) 
Former 
use 
(n=64) 
Never 
use 
(n=40) 
Former 
use 
(n=25) 
 
CPT, 
accuracy 
(%)(SD) 
92.6 
(11.0) 
94.0 
(8.3) 
95.3 
(8.5) 
96.4
(6.3) 
94.4 
(11.4)  
90.6
(16.7) 
.006 
CPT, mean 
reaction 
time 
(ms)(SD) 
434.9 
(76.9) 
423.5
(88.9) 
437.5 
(87.5) 
429.8
(88.9) 
425.5 
(84.7) 
467.1 
(85.6) 
.044 
 
*Genotyping failed in 10 patients  
†Patients without current use: reported no use of cannabis in the last year and urinalysis confirmed 
the absence of current cannabis use. 
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Figure 1. Continuous Performance Test performance as a function of cannabis use and AKT1 
rs2494732 genotype. 
 
Figure 1A. Continuous Performance Test – mean reaction time (in ms).  
 
 
Figure 1B. Continuous Performance Test – accuracy (% correct). 
 
 
 

